IRVINE, Calif.--(BUSINESS WIRE)--Sep. 28, 2017--
Masimo (NASDAQ:
MASI) announced today the full market release of RAS-45, an adhesive
adult and pediatric acoustic respiration sensor for rainbow Acoustic
Monitoring® (RAM™). RAS-45 offers the same performance as the
currently available RAS-125c sensor but in a smaller size, with more
flexible adhesive.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20170928005381/en/
Masimo rainbow Acoustic Monitoring® RAS-45 Acoustic Respiration Sensor (Photo: Business Wire)
RAM noninvasively and continuously measures respiration rate using an
innovative adhesive sensor with an integrated acoustic transducer, such
as Masimo’s RAS-125c and now RAS-45, that is applied to the patient’s
neck area. Using acoustic signal processing that leverages Masimo Signal
Extraction Technology (SET®), the respiratory signal is
separated and processed to display continuous respiration rate (RRa®)
and respiratory waveform, with the option to listen to the sound of
breathing from the acoustic sensor.
RRa has been shown to be accurate1,2, easy-to-use1,
easy-to-tolerate1,3, and reliable1, and has also
been shown to enhance patient compliance with respiration monitoring. In
a study comparing pediatric patient tolerance of sidestream capnography
with a nasal cannula to respiration rate monitoring with an RAS-125c
acoustic sensor, 15 out of 40 patients removed the cannula, while only
one removed the acoustic sensor.3 In a study of 98 patients
consciously sedated during upper gastrointestinal endoscopy, researchers
found that RRa monitoring with the RAS-125c sensor more accurately
assessed respiration rate than capnography using end-tidal carbon
dioxide (EtCO2) measurement or impedance pneumography.2
RAS-45 maintains the same performance parameters, range, and accuracy
specification as RAS-125c.
With its smaller size, RAS-45 is well suited for monitoring pediatric
patients and patients with shorter necks. The RAS-45 adhesive is
transparent, lighter, and more flexible than the RAS-125c adhesive. Like
RAS-125c, RAS-45 operates with Masimo MX technology boards to measure
RRa, display the acoustic respiration wave form, and optionally allow
clinicians to listen to the sound of breathing. Both sensors are for
adult and pediatric patients who weigh more than 10 kg.
Joe Kiani, Founder and CEO of Masimo, commented, “RAM harnesses the
power of our breakthrough signal processing technology and applies it to
a respiratory measurement derived from the sound of breathing. With the
addition of the RAS-45 sensor, RRa is now a more convenient and
comfortable measurement for clinicians and patients—especially children.”
Continuous monitoring of respiration rate can be helpful in cases such
as sedation-based procedures and post-surgical patients receiving
patient-controlled analgesia for pain management. The Anesthesia Patient
Safety Foundation (APSF) and The Joint Commission recommend continuous
oxygenation and ventilation (respiration) monitoring for all patients
receiving opioid-based pain medications.4,5
@MasimoInnovates |
#Masimo
References
-
Macknet MR et al. Accuracy and Tolerance of a Novel Bioacoustic
Respiratory Sensor in Pediatric Patients Anesthesiology.
2007;107:A84 (abstract).
-
Goudra BG et al. Comparison of Acoustic Respiration Rate, Impedance
Pneumography and Capnometry Monitors for Respiration Rate Accuracy and
Apnea Detection during GI Endoscopy Anesthesia. Open J Anesthesiol.
2013;3:74-79.
-
Patino M et al. Accuracy of Acoustic Respiration Rate Monitoring in
Pediatric Patients. Paediatr Anaesth. 2013 Sep 3.
-
Stoelting, RK et al. APSF newsletter. 2011. www.apsf.org.
-
The Joint Commission Sentinel Event Alert. Issue 49, August 8, 2012. www.jointcomission.org.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® has also been
shown to help clinicians reduce severe retinopathy of prematurity in
neonates,1 improve CCHD screening in newborns,2
and, when used for continuous monitoring with Masimo Patient SafetyNet™*
in post-surgical wards, reduce rapid response activations and costs.3,4,5
Masimo SET® is estimated to be used on more than 100 million
patients in leading hospitals and other healthcare settings around the
world,6 and is the primary pulse oximetry at 16 of the top 20
hospitals listed in the 2017-18 U.S. News and World Report Best
Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow®
Pulse CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be measured
invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin
(SpMet®), Pleth Variability Index (PVi®), and more
recently, Oxygen Reserve Index™ (ORi™), in addition to SpO2,
pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®,
an intuitive patient monitoring and connectivity platform with the
Masimo Open Connect™ (MOC-9™) interface, enabling other companies to
augment Root with new features and measurement capabilities. Masimo is
also taking an active leadership role in mHealth with products such as
the Radius-7™ wearable patient monitor, iSpO2®
pulse oximeter for smartphones, and the MightySat™ fingertip pulse
oximeter. Additional information about Masimo and its products may be
found at www.masimo.com.
Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
ORi has not received FDA 510(k) clearance and is not available for sale
in the United States.
*The use of the trademark Patient SafetyNet is under license from
University HealthSystem Consortium.
References
-
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
-
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;338.
-
Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue
Events and Intensive Care Unit Transfers: A Before-And-After
Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
-
Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia
Patient Safety Foundation Newsletter. Spring-Summer 2012.
-
McGrath SP et al. Surveillance Monitoring Management for General Care
Units: Strategy, Design, and Implementation. The Joint Commission
Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
-
Estimate: Masimo data on file.
- http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo RAS-45, RAM™, and RRa®. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks
related to our assumptions regarding the repeatability of clinical
results; risks related to our belief that Masimo's unique noninvasive
measurement technologies, including Masimo RAS-45, RAM, and RRa,
contribute to positive clinical outcomes and patient safety; risks
related to our belief that Masimo noninvasive medical breakthroughs
provide cost-effective solutions and unique advantages; as well as other
factors discussed in the "Risk Factors" section of our most recent
reports filed with the Securities and Exchange Commission ("SEC"), which
may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170928005381/en/
Source: Masimo
Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com